-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Research by scientists from the Graduate School of Medicine at Osaka City University has shown that combining the generic antibiotic rifampicin with the dietary supplement resveratrol, intranasal administration may prevent neurodegenerative diseases (such as Alzheimer's disease) A feasible method
Research leader Dr.
Neurodegenerative dementias include Alzheimer's disease (AD), frontotemporal dementia (FTD) and dementia with Lewy bodies (DLB)
Despite the "active efforts" made by researchers and pharmaceutical companies, there is no effective treatment for neurodegenerative dementia
The newly reported study builds on the team’s previous experiments on mice.
However, oral rifampicin is associated with side effects such as liver damage and drug-drug interactions
The team also wants to identify potential compounds that may help ensure the long-term safety of rifampicin for nasal use
Resveratrol is a natural antioxidant in plants and is widely used as a dietary supplement
In their latest report, the research team used a fixed dose of rifampicin and resveratrol intranasally injected 5 days a week for 4 weeks to give patients with Alzheimer’s disease, frontotemporal dementia and Lewy small A mouse model of physical dementia
According to the team’s previous research experience, nasal administration of a fixed-dose combination of rifampicin and resveratrol can increase the transfer of the drug to the brain, further improving safety and medicinal effects
Encouragingly, both drugs are cheap
“The number of people with dementia around the world has been increasing, and some sources predict that the number of people with dementia will double every 20 years
The author admits that further research is needed to determine the appropriate ratio of the two drugs, while conducting pharmacokinetic and general toxicity studies
Medilabo RFP is currently developing a fixed-dose combination of rifampicin and resveratrol nasal spray
